文献速递核素与放射性配体治疗肿瘤 PET/CT

[211At]PSAt-3-Ga的研制与临床前评价:一种用于前列腺癌靶向α治疗的抑制剂

Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer.
PubMed 文献 · J Nucl Med · 2024-04-01

本研究采用碘代和68Ga标记的替代策略设计并筛选PSMA靶向化合物,确定[68Ga]PSGa-3为先导化合物后合成[211At]PSAt-3-Ga,放化产率35%,其在PSMA阳性LNCaP细胞中显示纳摩尔级亲和力和特异性内化,体内肿瘤摄取1小时为19±8 %ID/g、24小时为7.6±2.9 %ID/g,甲状腺、脾和胃等脱靶组织摄取低,提示体内脱砹少。

要点

  • 碘代和68Ga标记替代策略可方便地用于开发砹标记化合物。
  • [211At]PSAt-3-Ga放化产率35%,1小时肿瘤摄取19±8 %ID/g,24小时为7.6±2.9 %ID/g。
  • 甲状腺、脾和胃摄取低,提示[211At]PSAt-3-Ga体内脱砹少。

核心结论

  • 研究结果支持将碘代和68Ga标记变体作为开发砹标记化合物的便捷策略,并确认[211At]PSAt-3是一种有前景的靶向α治疗放射性药物。

研究设计与样本

  • 临床前研究:采用碘代和68Ga标记替代策略设计并筛选PSMA靶向化合物,对最有前景的候选物进行211At标记并开展生物分布研究。

主要发现

  • 所有68Ga标记替代物在PSMA阳性LNCaP细胞中显示纳摩尔级亲和力和特异性内化,PET显像确定[68Ga]PSGa-3为先导化合物。
  • [211At]PSAt-3-Ga放化产率35%,注射后1小时肿瘤摄取19±8 %ID/g,24小时为7.6±2.9 %ID/g。
  • 甲状腺摄取2.0±1.1 %ID/g、脾摄取3.0±0.6 %ID/g、胃摄取2.0±0.4 %ID/g,脱靶组织摄取低,提示[211At]PSAt-3-Ga体内脱砹少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The application of prostate-specific membrane antigen (PSMA)-targeted α-therapy is a promising alternative to β--particle-based treatments. 211At is among the potential α-emitters that are favorable for this concept. Herein, 211At-based PSMA radiopharmaceuticals were designed, developed, and evaluated. Methods: To identify a 211At-labeled lead, a surrogate strategy was applied. Because astatine does not exist as a stable nuclide, it is commonly replaced with iodine to mimic the pharmacokinetic behavior of the corresponding 211At-labeled compounds. To facilitate the process of structural design, iodine-based candidates were radiolabeled with the PET radionuclide 68Ga to study their preliminary in vitro and in vivo properties before the desired 211At-labeled lead compound was formed. The most promising candidate from this evaluation was chosen to be 211At-labeled and tested in biodistribution studies. Results: All 68Ga-labeled surrogates displayed affinities in the nanomolar range and specific internalization in PSMA-positive LNCaP cells. PET imaging of these compounds identified [68Ga]PSGa-3 as the lead compound. Subsequently, [211At]PSAt-3-Ga was synthesized in a radiochemical yield of 35% and showed tumor uptake of 19 ± 8 percentage injected dose per gram of tissue (%ID/g) at 1 h after injection and 7.6 ± 2.9 %ID/g after 24 h. Uptake in off-target tissues such as the thyroid (2.0 ± 1.1 %ID/g), spleen (3.0 ± 0.6 %ID/g), or stomach (2.0 ± 0.4 %ID/g) was low, indicating low in vivo deastatination of [211At]PSAt-3-Ga. Conclusion: The reported findings support the use of iodine-based and 68Ga-labeled variants as a convenient strategy for developing astatinated compounds and confirm [211At]PSAt-3 as a promising radiopharmaceutical for targeted α-therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. El Fakiri M, Ayada N, Müller M, et al. Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer. J Nucl Med. 2024. PMID: 38423784. doi:10.2967/jnumed.123.267043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。